IL6 and diabetic kidney disease: The present randomized, double-blind, placebo-controlled clinical trial was carried out to address this gap by focusing exclusively on patients with DKD, providing more accurate data on the effects of melatonin supplementation on oxidative stress and inflammatory biomarkers, including TAC, TOS, and MDA for oxidative stress, as well as IL-6 and hs-CRP for inflammatory markers.